88431-47-4
Chemical Structure
Clomoxir
Synonym(s): POCA
- CAS. Nr.: 88431-47-4
- Formula:C14H17ClO3
- Molecular Weight:268.74
IUPAC Name: 2-(5-(4-chlorophenyl)pentyl)oxirane-2-carboxylic acid
InChIKey: ACZKTJZXXSHIGF-UHFFFAOYSA-N
SMILES: O=C(O)C1(OC1)CCCCCC2=CC=C(Cl)C=C2
Biological Activity: Clomoxir (POCA) is a carnitine palmitoyltransferase I (CPT I) inhibitor with hypoglycemic activity. Clomoxir mediates the inhibition of CPT I via its active form POCA-CoA. Clomoxir inhibits long-chain fatty acid oxidation, ketogenesis, gluconeogenesis, de novo synthesis of cholesterol and fatty acids, and also mildly inhibits acetyl-CoA carboxylase. Clomoxir reduces blood glucose levels in various rodent and porcine models, alters plasma NEFA and cholesterol concentrations, induces hepatic lipid accumulation, peroxisome proliferation and mild myocardial hypertrophy in rats, and stimulates the pentose phosphate pathway in cultured human fibroblasts. Clomoxir can be used in diabetes-related research[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Clomoxir | Clomoxir (POCA) is a carnitine palmitoyltransferase I (CPT I) inhibitor with hypoglycemic activity. Clomoxir mediates the inhibition of CPT I via its active form POCA-CoA. Clomoxir inhibits long-chain fatty acid oxidation, ketogenesis, gluconeogenesis, de novo synthesis of cholesterol and fatty acids, and also mildly inhibits acetyl-CoA carboxylase. Clomoxir reduces blood glucose levels in various rodent and porcine models, alters plasma NEFA and cholesterol concentrations, induces hepatic lipid accumulation, peroxisome proliferation and mild myocardial hypertrophy in rats, and stimulates the pentose phosphate pathway in cultured human fibroblasts. Clomoxir can be used in diabetes-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Foley JE, et al. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes care. 1992 Jun;15(6):773-84.
- [2]. Agius L, et al. Stereospecificity of the inhibition by etomoxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes. Biochemical pharmacology. 1991 Oct 09;42(9):1717-20.
- [3]. Spurway TD, et al. Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate, inhibits triacylglycerol depletion in hepatocytes and lipolysis in adipocytes. FEBS letters. 1997 Mar 03;404(1):111-4.
